Maxpro Capital Acquisition (JMAC) Stock Price, News & Analysis

Company Overview

Maxpro Capital Acquisition Corp. is a Delaware‐incorporated special purpose acquisition company (SPAC) that completed its initial public offering in 2021. The company has no ongoing business operations of its own; instead, it holds the proceeds from its IPO in a trust account and is focused on identifying and completing a business combination with one or more target companies.

Through its blank check structure, Maxpro Capital Acquisition seeks to partner with businesses in sectors such as technology, healthcare, industrials and business services. The firm’s strategy is to leverage industry expertise and capital markets experience to support a target’s growth initiatives, operational improvements and strategic acquisitions after the business combination.

Maxpro Capital Acquisition’s management team comprises professionals with backgrounds in investment banking, corporate finance, venture capital and corporate development. While the company has not yet announced a definitive acquisition agreement, its leadership emphasizes disciplined deal sourcing, rigorous due diligence and long‐term value creation for public shareholders.

Key Stats

• Today's Range: $18.43 to $18.43
• 50-Day Range: $3.93 to $18.43
• 52-Week Range: $7.50 to $19.22
• Volume: N/A
• Average Volume: 74,040 shs
• Market Capitalization: $247.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

JMAC Stock Analysis - Frequently Asked Questions

How have JMAC shares performed this year?

Maxpro Capital Acquisition's stock was trading at $9.75 at the beginning of 2025. Since then, JMAC shares have increased by 89.1% and is now trading at $18.4331.

How do I buy shares of Maxpro Capital Acquisition?

Shares of JMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Maxpro Capital Acquisition own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Maxpro Capital Acquisition investors own include Meta Platforms (META), PhaseBio Pharmaceuticals (PHAS), Dermata Therapeutics (DRMA), Daifuku (DAIUF), CXApp (CXAI), Centogene (CNTG) and

Company Calendar

• Today: 9/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Holding & other investment offices
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JMAC
• CIK: 1874259
• Web: N/A
• Phone: 886-2-7713-7952
• Fax: N/A
• Employees: 2,021
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 13,428,000
• Free Float: 10,840,000
• Market Cap: $247.52 million
• Optionable: Not Optionable
• Beta: 0.01